공시 • Jan 28
Biomind Labs Inc. announced that it expects to receive CAD 2.52 million in funding Biomind Labs Inc. announced a non-brokered private placement of up to 28,000,000 units at a price of CAD 0.09 per unit for gross proceeds of up to CAD 2,520,000 on January 27, 2026. Each unit will be composed of one common share and one common share purchase warrant. Each warrant will entitle the holder thereof to acquire one common share at a price of CAD 0.12for a period of 24 months following the completion of the offering. The offering is expected to close on or about February 6, 2026, and is subject to customary closing conditions, including all necessary regulatory approvals. Securities issued under the offering will be subject to a statutory hold period of four months and one day from the date of issuance. The company may also pay finders' fees to certain eligible finders in accordance with applicable securities laws and the policies of CBOE Canada. 공시 • Dec 11
Biomind Labs Inc., Annual General Meeting, Feb 04, 2026 Biomind Labs Inc., Annual General Meeting, Feb 04, 2026. 공시 • Nov 19
Biomind Labs Inc. Appoints Scott Ackerman as an Independent Director of the Board of Directors, and as an Independent Member of the Audit Committee Biomind Labs Inc. announced that Scott Ackerman has been appointed as an independent director of the Board of Directors of the Company, and as an independent member of the Company's Audit Committee. Mr. Ackerman is the CEO of Emprise Capital Corp., a private merchant bank providing restructuring services to public companies for over 20 years, and is also a director, senior officer, and chair of a number of audit committees for several Canadian listed public companies. 공시 • Jul 19
Biomind Labs Inc. Announces the Decision to Advance A New Phase II Clinical Trial Biomind Labs Inc. announced the decision to advance a new Phase II clinical trial. This decision follows new and unexpected findings from a pre-clinical study of its proprietary compound 3,4,5-trimethoxyphenethylamine-based BMND06. The toxicological studies reveal that the BMND06 candidate is physiologically safe, exhibiting low acute and chronic oral toxicity with no mutagenic effects. The primary objective was to establish a starting safe dose for the first-in-human trial and evaluate the potential toxicity of BMND06. In addition to in vivo studies, in vitro assays surprisingly demonstrated that BMND06 significantly reduces LPS (lipopolysaccharide)-induced IL-6 (interleukin-6) levels in various colon cancer cell lines, outperforming dexamethasone-a commonly used anti-inflammatory corticosteroid-by fivefold in reducing IL-6 induction caused by LPS. Obesity is the accumulation of abnormal or excessive fat that can interfere with maintaining optimal health. Excess macronutrients in adipose tissue stimulate the release of inflammatory mediators such as tumor necrosis factor-alpha (TNF-a) and interleukin 6 (IL-6), while reducing adiponectin production, leading to a pro-inflammatory state and oxidative stress. Elevated IL-6 levels prompt the liver to synthesize and secrete C-reactive protein (CRP). As a risk factor, inflammation is a key mechanism in the development of cardiovascular diseases, including coagulation disorders, atherosclerosis, metabolic syndrome, insulin resistance, and diabetes mellitus. It is also linked to non-cardiovascular diseases such as psoriasis, depression, cancer, and renal disease. Overweight and obesity have serious social and psychological consequences for those affected. The preclinical studies have provided robust scientific evidence supporting the safety and anti-inflammatory efficacy of the active pharmaceutical ingredient of BMND06. This data justifies advancing to a Phase II New Drug Clinical Trial in humans, focusing on obesity, without the need for additional preclinical assays. 공시 • Sep 15
Biomind Labs Completes the Development of the First 5-MeO-DMT Organic Synthesis Scheme for Pharmaceutical Applications Biomind Labs Inc. announced the successful completion of the first 5-Metoxi-N,N-dimethyltryptamine ("5-MeO-DMT") organic synthesis scheme. Key accomplishments of the first 5-MeO-DMT organic synthesis scheme include: Organic Synthesis Success: A pioneering organic synthesis scheme that enables the efficient production of 5-MeO-D MT freebase. This novel process ensures high purity and maintains the compound's integrity, making it suitable for pharmaceutical applications. Pharmaceutical-Grade Quality: The 5-MeO-DMD freebase produced using this new method and under Good Manufacturing Practices (GMP) meets stringent pharmaceutical standards, guaranteeing its suitability for use in the development of advanced medicines and therapies. Potential Therapeutic Applications: The availability of high-purity 5-MeO-DCT as an API paves the way for innovative research and development in various therapeutic areas. Although Biomind primarily targets the treatment of mental health disorders, such as depression and anxiety, other areas of medicine could benefit from the availability of high-purity5-MeO-D MT. Commitment to Safety and Compliance: Biomind places an emphasis on safety and compliance with regulatory standards. The Company has undertaken rigorous testing and quality control measures to ensure the levels of product safety and consistency. Additionally, the associated complexities in the authorization process, substantial expenses, and intricate logistics further compound these challenges. 공시 • Aug 13
Biomind Labs Files Patent Application in the United States Patent and Trademark Office, Its 4th Patent Application Biomind Labs Inc. announced that it has filed a patent application in the United States Patent and Trademark Office (USPTO), its 4th patent application. The patent application filed in the USPTO relates to Biomind Labs’ proprietary technology on labeled DMT and an associated method for a personalized treatment of neurological and psychiatric disorders. The method monitors DMT levels in relevant body fluids facilitating the design of personalized treatments, regardless of metabolic, genetic, or environmental factors. Further, it is a novel method that allows the development of DMT based treatments available to the modern psychiatric clinical practice. 